It will allow us to assess the clinical data, help government research evaluate safety, the dosing protocols, the effectiveness and the duration of any benefits. Another announcement, ARPAH will also fund an additional effort to explore ibogaine as a potential source for substance use disorder and for other indications. We expect to announce that award before the end of the year. The initial commitment spans five years. The teams must meet accelerated research milestones to receive continued funding. (11:49–12:00)
STATEMENT
Asserts that ARPAH will fund efforts to explore ibogaine for substance use disorder and other indications.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.